

# Estimates, trends, and drivers of the global burden of type 2 diabetes attributable to PM<sub>2.5</sub> air pollution, 1990–2019: an analysis of data from the Global Burden of Disease Study 2019



GBD 2019 Diabetes and Air Pollution Collaborators\*



## Summary

**Background** Experimental and epidemiological studies indicate an association between exposure to particulate matter (PM) air pollution and increased risk of type 2 diabetes. In view of the high and increasing prevalence of diabetes, we aimed to quantify the burden of type 2 diabetes attributable to PM<sub>2.5</sub> originating from ambient and household air pollution.

**Methods** We systematically compiled all relevant cohort and case-control studies assessing the effect of exposure to household and ambient fine particulate matter (PM<sub>2.5</sub>) air pollution on type 2 diabetes incidence and mortality. We derived an exposure–response curve from the extracted relative risk estimates using the MR-BRT (meta-regression—Bayesian, regularised, trimmed) tool. The estimated curve was linked to ambient and household PM<sub>2.5</sub> exposures from the Global Burden of Diseases, Injuries, and Risk Factors Study 2019, and estimates of the attributable burden (population attributable fractions and rates per 100 000 population of deaths and disability-adjusted life-years) for 204 countries from 1990 to 2019 were calculated. We also assessed the role of changes in exposure, population size, age, and type 2 diabetes incidence in the observed trend in PM<sub>2.5</sub>-attributable type 2 diabetes burden. All estimates are presented with 95% uncertainty intervals.

**Findings** In 2019, approximately a fifth of the global burden of type 2 diabetes was attributable to PM<sub>2.5</sub> exposure, with an estimated 3·78 (95% uncertainty interval 2·68–4·83) deaths per 100 000 population and 167 (117–223) disability-adjusted life-years (DALYs) per 100 000 population. Approximately 13·4% (9·49–17·5) of deaths and 13·6% (9·73–17·9) of DALYs due to type 2 diabetes were contributed by ambient PM<sub>2.5</sub>, and 6·50% (4·22–9·53) of deaths and 5·92% (3·81–8·64) of DALYs by household air pollution. High burdens, in terms of numbers as well as rates, were estimated in Asia, sub-Saharan Africa, and South America. Since 1990, the attributable burden has increased by 50%, driven largely by population growth and ageing. Globally, the impact of reductions in household air pollution was largely offset by increased ambient PM<sub>2.5</sub>.

**Interpretation** Air pollution is a major risk factor for diabetes. We estimated that about a fifth of the global burden of type 2 diabetes is attributable PM<sub>2.5</sub> pollution. Air pollution mitigation therefore might have an essential role in reducing the global disease burden resulting from type 2 diabetes.

**Funding** Bill & Melinda Gates Foundation.

**Copyright** © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

## Introduction

Diabetes has been highlighted as a major global health threat by WHO.<sup>1</sup> The disease is characterised by hyperglycaemia resulting from dysfunctional insulin secretion or action.<sup>2</sup> Long-term consequences can be dysfunction and failure of different organs, especially the eyes, kidneys, nerves, heart, and blood vessels.<sup>2</sup> Type 2 diabetes accounts for 90–99% of diabetes cases globally and contributed to approximately 94% of disability-adjusted life-years (DALYs) and 96% of years lived with disability (YLDs) due to diabetes.<sup>2–4</sup>

In total, the global burden of diabetes was estimated at 1·55 million excess deaths, with 34 million years of life lost (YLLs) and 37 million YLDs in 2019.<sup>3</sup> Since the 1990s,

global age-standardised death rates increased by 8·6%, all-age death rates increased by 62%, and the burden of disease has approximately doubled.<sup>3</sup> Recent projections predict a further increase in diabetes-related mortality rates of approximately 75% by 2040.<sup>5</sup> Metabolic and behavioural risk factors, such as obesity, smoking, diet, and physical inactivity, have been highlighted as major contributors to the burden of type 2 diabetes.<sup>1</sup> In the past 15 years, studies have indicated an important role of factors that promote inflammatory responses,<sup>4,6</sup> such as air pollution. A meta-analysis that included five cross-sectional and five prospective cohort studies showed an increased risk of type 2 diabetes due to exposure to particulate matter (PM) or nitrogen dioxide air pollution.<sup>7</sup>

*Lancet Planet Health* 2022;  
6: e586–600

\*Collaborators are listed at the end of the Article

Correspondence to:  
Dr Katrin Burkart, Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA 98195, USA  
katburk@uw.edu

### Research in context

#### Evidence before this study

Type 2 diabetes is a major global health concern, contributing to approximately 1·5 million deaths, 31 million years of life lost, and 35 million years lived with disability in 2019. Behavioural and metabolic risk factors are widely acknowledged to increase diabetes incidence, but epidemiological and experimental evidence also supports a relationship between long-term exposure to fine particulate matter (PM<sub>2.5</sub>) air pollution and increased diabetes incidence and mortality. The well documented increase in incidence and mortality from inflammation has been highlighted as a relevant biological mechanism linking air pollution exposure to diabetes. Although the effect of exposure to ambient and household PM<sub>2.5</sub> pollution on diabetes has been estimated in different locations and population groups, the current global disease burden attributable to PM<sub>2.5</sub>, its temporal trends, and its magnitude relative to other known diabetes risk factors have not yet been evaluated. The framework of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) allows a systematic assessment of the contribution of individual risk factors in a spatially and temporally explicit manner, producing comparable estimates at global, regional, and country levels.

#### Added value of this study

We systematically reviewed existing epidemiological studies on the relationship between PM<sub>2.5</sub> exposure and type 2 diabetes from diverse sources. We created an exposure–response relationship using the meta-regression tool MR-BRT (meta-regression—Bayesian, regularised, trimmed). The regularisation feature provided by the MR-BRT tool allowed us to fit a spline covering the entire global exposure range by putting a strong prior on the shape of the curve at the upper

end of the exposure range and keeping it from increasing. By linking the derived exposure–response curve to modelled ambient and household air pollution levels, we estimated the population attributable fraction (PAF) and derived the type 2 diabetes burden attributable to PM<sub>2.5</sub> air pollution for 204 countries and territories from 1990 to 2019. Using a proportional PAF approach, we estimated the relative contribution of ambient and household air pollution. To better understand the drivers behind the observed trend in PM<sub>2.5</sub>-attributable diabetes burden, we assessed the role of changes in exposure, population size, age, and diabetes incidence. Approximately a fifth of the global diabetes burden in 2019 was related to exposure to PM<sub>2.5</sub> air pollution. Since 1990, the attributable burden has doubled, driven largely by population growth and ageing. Reductions in household air pollution burden were largely offset by increased burden from exposure to ambient PM<sub>2.5</sub>. Around 80% of the attributable burden occurred in Asia, sub-Saharan Africa, and South America.

#### Implications of all the available evidence

Our results highlight the importance of PM<sub>2.5</sub> air pollution as a risk factor for diabetes and as target for risk reduction. Most of the PM<sub>2.5</sub>-attributable burden stems from ambient air pollution, except in sub-Saharan Africa, where household air pollution was the major contributor. Although increasing ambient air pollution levels in low-income and middle-income countries contributed to the rise in the diabetes burden attributable to air pollution observed between 1990 and 2019, population growth and ageing were the major drivers of this trend, and predicted demographic trends suggest further increases in the diabetes burden associated with PM<sub>2.5</sub> air pollution in the future.

Given the relationship between exposure to air pollution and cardiovascular disease<sup>8</sup> and similarities in biological pathways between diabetes and cardiovascular disease, air pollution has been posited to have a causal role in diabetes.<sup>9</sup> Experimental studies indicate the role of inflammation in biological mechanisms linking exposure to PM with diabetes.<sup>4</sup> In a mouse model, exposure to high concentrations of PM<sub>2.5</sub> induced insulin resistance and systemic inflammation and increased visceral adiposity in obese study animals.<sup>10</sup> Ongoing exposure led to impaired glucose tolerance, lower circulating concentrations of adipokines (adiponectin and leptin), and mitochondrial alteration in the same mice.<sup>11</sup> This and other evidence generated from experimental studies has led to epidemiological studies assessing the relationship between diabetes risk and air pollution.<sup>12–15</sup> We aimed to assess the burden of type 2 diabetes attributable to ambient and household PM<sub>2.5</sub> air pollution using estimates derived from epidemiological studies. We also aimed to evaluate the relative roles of changes in exposure, population size,

age, and diabetes incidence in the observed trend in PM<sub>2.5</sub>-attributable diabetes burden. This manuscript was produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) Collaborator Network and in accordance with the GBD Protocol.

## Methods

### Overview

GBD is the most comprehensive global epidemiological study. It estimates the burden of disease from 286 causes of death, 369 diseases and injuries, and 87 risk factors in 204 countries and territories. Risk factors include metabolic, behavioural and environmental factors, such as air pollution.

### Literature review and study extraction

To compile all relevant studies, we followed a two-stage search strategy. In stage 1, we searched PubMed on June 1, 2017, and in 2019 for the most recent meta-analysis or systematic review of studies investigating the effect of ambient air pollution, household air pollution, or

second-hand smoke on diabetes. We defined a search string consisting of “diabetes”, “meta-analysis”, or “review” and the exposure indicator (eg, “particulate matter”, “household air pollution”, “indoor air pollution”, or “cooking fuel”). The exact search strings are provided in the appendix p 2). In stage 2, we included additional studies that were identified through other sources, such as those referenced in another study or published and unpublished work sent to us by members of the GBD Collaborator Network.

The primary outcome of interest was type 2 diabetes in adults aged 18 years or older. As some studies did not differentiate between type 1 and type 2, we assumed that cases were dominated by type 2.<sup>24</sup> We included studies that assessed morbidity (ie, incidence) and mortality. We limited our results to case-control and cohort studies and articles written in English. Studies were excluded if the full text could not be obtained, if exposure to PM<sub>2.5</sub> was short term (eg, several days), or if exposure to active tobacco smoking was not measured in terms of cigarettes per day. Studies that assessed type 1 or gestational diabetes were also excluded. Information from each of the individual studies that were identified, including effect estimates and additional study-specific information, was extracted and used in the meta-regression.

### Exposure assessment

For estimation of ambient air pollution exposure, we used the Data Integration Model for Air Quality (DIMAQ2). This model integrates data from satellite-based measurements of aerosol optical depth, ground measurements from 9960 PM monitoring stations across 108 countries, and chemical transport model simulations.<sup>16</sup> Global values of PM<sub>2.5</sub>, provided at a 0.1° × 0.1° resolution, were population-weighted to generate mean exposure for each location. Methods and data sources are described in more detail in the appendix (pp 2–5) and have been published elsewhere.<sup>16</sup>

Exposure modelling for household air pollution from solid fuels comprised two components. The first component, the so-called proportional model, estimated the proportion of households using solid cooking fuels, relying on data extracted from multiple national-level and other surveys and the WHO Energy Database.<sup>17</sup> The second component, the mapping model, estimated the exposure concentration of PM<sub>2.5</sub> corresponding to solid-fuel use, measured in µg per cubic metre of air (µg/m<sup>3</sup>) for a given location and year based on the Socio-demographic Index. Further information is provided in the appendix (pp 3–4).

### Exposure–response curve

Several studies have derived relative risks over various exposure ranges. These risks differ in magnitude, and the exposure range over which they are assessed varies. Furthermore, at the upper end of the global ambient air pollution exposure range, reliable estimates are not

available, due to a scarcity of studies in highly polluted areas. Another challenge in meta-regressing risk estimations from different studies lies in differing study designs and varying adjustment for potential confounders. To account for between-study heterogeneity and to develop a relative risk function that covered the entire global exposure range, we combined risk estimates from all available studies using the newly developed regression tool, MR-BRT (meta-regression—Bayesian, regularised, trimmed).<sup>18</sup>

Risk estimates from studies assessing the impact of ambient air pollution, household air pollution, and second-hand smoke on type 2 diabetes were used to fit a spline, with each risk estimate informing the curve along the study-specific exposure range. Various model settings and priors were tested for fitting the MR-BRT splines. The final models used third-order splines with two interior knots and a constraint on the right-most segment, forcing the fit to be linear rather than cubic at the upper end. We used an ensemble approach to knot placement, wherein 100 different models were run with randomly placed knots and then combined by weighting based on a measure of fit that penalises excessive changes in the third derivative of the curve. Knots were free to be placed anywhere within the 5th and 95th percentile of the data, as long as a minimum width of 10% of that domain existed between them. We included shape constraints so that the risk curves were concave down and monotonically increasing—the most biologically plausible shape for the PM<sub>2.5</sub> risk curve. On the non-linear segments, we included a Gaussian prior on the third derivative of mean 0 and variance 0.01 to prevent overfitting; on the linear segment, a stronger prior of mean 0 and variance 1 × 10<sup>-6</sup> was used to ensure that the risk curves did not continue to increase beyond the range of the data.

In addition, we extracted a set of study-specific covariates to explain between-study heterogeneity in risk estimates. We considered whether the study assessed the overall population or a subpopulation using a binary variable; two binary variables indicated whether exposure was measured at the population or individual level and whether exposure was measured at the beginning of the study versus at multiple timepoints during the study period. We also included binary variables indicating whether the exposure or the outcome was self-reported and a variable indicating whether the assessment was blind to exposure. We also accounted for the degree to which study participants were lost to follow-up. Finally, we accounted for control of confounding within each study by creating two covariates. First, we created a binary variable indicating whether the study was randomised. As no studies were randomised, this variable was not included in the meta-regression. In addition, we created a categorical variable indicating the degree of statistical control for potential confounding. This covariate had three levels: the first level indicated that the study had controlled for major confounders—specifically, age, sex,

See Online for appendix

education, income, and smoking status—measured at either the individual or the community level. The next level indicated that the study had controlled for age, sex, and smoking only. The third level indicated that the study controlled only for age and sex but no other confounders. The appendix (pp 9–11) gives a detailed overview over all covariates included in the meta-regression. As none of these covariates was significant in the model, the final model was fitted without them.

### PAF calculation and burden estimation

The population attributable fraction (PAF) quantifies the proportion of cases that can be attributed to the risk factor. That is, PAFs represent the fraction of cases that would be avoided if exposure was reduced to the theoretical minimum risk exposure level. As individuals who are exposed to household sources of PM<sub>2.5</sub> are also exposed to ambient sources, we used a proportional approach to calculate PAFs for each risk factor. Using the mean annual ambient PM<sub>2.5</sub> exposure, the proportion of individuals exposed to PM from household solid fuel use, and the value derived from the household PM<sub>2.5</sub> mapping function for each location and year, we calculated a corresponding relative risk from the exposure–response curve for each 0.1°×0.1° grid cell. This relative risk was converted to a PAF using the following formula:  $PAF = (RR - 1) / RR$ , where RR is the relative risk. This PAF, which was initially determined for both sources of PM<sub>2.5</sub>, and was then proportionally attributed to ambient and household. We then aggregated up to the location level (country or administrative unit), weighting by grid cell-level population. By using this strategy, the total PAF is the sum of the ambient and household PAFs, and we assume that both exposures are evenly distributed across different slopes of the exposure–response curve. More details about these calculations can

be found in the appendix (p 4). Eventually, the type 2 diabetes burden was determined by multiplying age-specific, sex-specific, year-specific, and location-specific PAFs with deaths, YLLs, YLDs, and DALYs for 204 countries and territories from 1990 to 2019. Over this period, we decomposed the trend in the attributable burden to evaluate the relative roles of changes in exposure, population size, age, and type 2 diabetes incidence. To account for uncertainties in our modelling, we produced 1000 draws of all estimates and intermediate steps. We present estimates (with 95% uncertainty intervals [UIs]) of PAFs and rates per 100 000 population of type 2 diabetes deaths, DALYs, YLDs, and YLLs attributable to PM<sub>2.5</sub> pollution. We also calculated the PM<sub>2.5</sub> pollution-deleted DALY rate, which is the expected rate if air pollution were reduced to the theoretical minimum risk exposure level and captures changes in other risk factors or treatment practices.


### Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

### Results

The literature search resulted in 13 studies with 16 effect estimates for ambient air pollution, two sources and effect estimates for household air pollution, and five sources and seven effect estimates for second-hand smoke. Studies assessing the effects of ambient air pollution, second-hand smoke, and household air pollution covered an exposure range of approximately 5–100 µg/m<sup>3</sup> (annual average). All ambient air pollution, household air pollution, and second-hand smoke studies revealed an increase in type 2 diabetes risk with increased exposure to PM with varying degrees of precision. The estimated relative risk increases rapidly between a PM<sub>2.5</sub> exposure concentration of 5 µg/m<sup>3</sup> and approximately 50 µg/m<sup>3</sup>; above this concentration, the curve flattens and shows only minimal increases (figure 1).

In 2019, about a fifth of the total type 2 diabetes burden was attributable to air pollution, with a death rate of 3.78 (95% UI 2.68–4.83) per 100 000 population and a DALY rate of 167 (117–223) per 100 000 population (table). 13.4% (9.49–17.5) of type 2 diabetes deaths were due to ambient air pollution, whereas 6.50% (4.22–9.53) were due to household air pollution. Africa, the Middle East, and south and east Asia exhibited a particularly high PM<sub>2.5</sub>-attributable burden (figure 2A). Noticeably, ambient air pollution contributed to a large extent of this burden in north Africa and the Middle East, whereas in sub-Saharan Africa, most of the air pollution-attributable burden stemmed from household air pollution (figures 2B, 2C). North America, Australia, and Scandinavia showed distinctly low air-pollution-attributable type 2 diabetes burden (figure 2). YLDs showed a greater increase than YLLs; this trend could be observed globally, but especially



**Figure 1:** Exposure–response function for PM<sub>2.5</sub> exposure and type 2 diabetes for an exposure range of 0–100 µg/m<sup>3</sup> (A) and 0–500 µg/m<sup>3</sup> (B)

The solid line shows the central estimate of the exposure–response curve, and the shaded area depicts 95% uncertainty intervals. The relative risk equals 1 for PM<sub>2.5</sub> concentrations of 0–2.4 µg/m<sup>3</sup>, which corresponds to the lower bound of the theoretical minimum risk exposure level uncertainty distribution. Each point represents an epidemiological study included in the model. The size of the point reflects the inverse variance used to weight the model. The relative risk axis is on a log scale. PM=particulate matter.

in north Africa and the Middle East and in south Asia (table).

Globally, we observed marked increases in the rate of type 2 diabetes from 1990 to 2019.<sup>3</sup> This pattern was observed for most regions, with the exception of high-income regions, central Europe, eastern Europe, and central Asia, for which rates were stagnant after 2010 (figure 3). Rates of type 2 diabetes attributable to ambient air pollution showed a similar pattern as for overall air pollution, whereas rates of type 2 diabetes attributable to household air pollution either showed a slight decline or stagnation. With regard to the time trend in the PAF of type 2 diabetes attributable to air pollution, we found a decrease in all super-regions from 1990 to 2019. This decline was driven by declines in PAFs in household air pollution. PAFs for ambient air pollution increased in most regions, except for high-income regions, where we observed a decrease. In central Europe, eastern Europe, and central Asia, PAFs for ambient air pollution were mostly stagnant (figure 3).

Figure 4 shows a decomposition of individual factors driving changes in type 2 diabetes DALYs attributable to air pollution between 1990 and 2019. A reduction in exposure to household air pollution led to a decrease in the attributable burden in all considered regions as well as globally. In high-income countries, improvements in ambient air pollution levels contributed to reduced attributable risks, whereas in all other regions we observed an increase in DALYs due to ambient PM<sub>2.5</sub> exposure. In Latin America and the Caribbean, southeast Asia, east Asia, and Oceania, and south Asia, where improvement in household air pollution led to the biggest reductions in the burden, these reductions were vastly offset by increases in ambient air pollution exposure. A similar pattern, but with slightly smaller numbers, was observed in north Africa and the Middle East and sub-Saharan Africa. In all GBD super-regions, PM<sub>2.5</sub>-deleted DALY rates—ie, changes in other risk factors—drove increases in type 2 diabetes. Population ageing and growth substantially contributed to increases in the type 2 diabetes burden attributable to PM<sub>2.5</sub>. Although population ageing played a major part, in high-income countries, central and eastern Europe, and central Asia, in sub-Saharan Africa, population growth drove most of the air pollution-attributable burden. We observed a net increase in air pollution-attributable type 2 diabetes DALYs in all super-regions, with a global increase of approximately 140%.

### Discussion

This study provides a systematic analysis of the type 2 diabetes burden attributable to ambient PM<sub>2.5</sub> pollution, composed of ambient air pollution and household air pollution. Ambient PM<sub>2.5</sub> ranked as the third leading risk factor for type 2 diabetes within the GBD hierarchy, after high fasting plasma glucose and high body-mass index.<sup>17</sup> Approximately a fifth of the


	Deaths			DALYs			YLDs			YLSs		
	Percentage (%)	Rate per 100 000	Percentage change (%)	Percentage (%)	Rate per 100 000	Percentage change (%)	Percentage (%)	Rate per 100 000	Percentage change (%)	Percentage (%)	Rate per 100 000	Percentage change (%)
<b>PM<sub>2.5</sub> air pollution</b>												
Global	19.9% (14.2 to 25.5)	3.78 (2.68 to 4.83)	54.8% (25.0 to 75.1)	19.6% (13.9 to 25.0)	167 (117 to 223)	64.2% (32.7 to 82.5)	18.9% (13.5 to 24.2)	86.0 (57.1 to 128)	90.0% (56.9 to 108)	20.2% (14.5 to 25.9)	81.5 (58.4 to 104)	43.6% (15.8 to 63.2)
Central Europe, eastern Europe, and central Asia	16.2% (11.2 to 21.6)	2.52 (1.72 to 3.36)	67.5% (37.8 to 100)	15.9% (10.9 to 21.2)	135 (85.7 to 190)	59.7% (33.5 to 91.7)	15.6% (10.7 to 20.8)	83.2 (47.4 to 125)	64.6% (37.4 to 99.5)	16.4% (11.4 to 21.8)	51.6 (35.5 to 68.8)	52.4% (26.1 to 82.6)
High income	9.62% (5.76 to 14.4)	1.91 (1.14 to 2.84)	-19.0% (-41.0 to 15.2)	9.30% (5.47 to 14.2)	93.2 (52.1 to 149)	7.31% (-24.4 to 47.9)	9.26% (5.44 to 14.1)	63.9 (32.4 to 106)	43.2 (2.15 to 101)	9.38% (5.56 to 14.2)	29.3 (17.6 to 44.3)	-30.6% (-49.9 to -2.48)
Latin America and Caribbean	16.0% (11.2 to 21.0)	5.46 (3.75 to 7.21)	49.8% (22.0 to 80.3)	16.0% (11.3 to 21.0)	218 (147 to 297)	52.9% (25.3 to 83.6)	15.9% (11.1 to 20.8)	101 (59.6 to 154)	81.5% (50.8 to 117)	16.1% (11.4 to 21.2)	117 (80.5 to 154)	34.6% (9.38 to 62.7)
North Africa and Middle East	22.4% (16.2 to 27.9)	3.51 (2.53 to 4.54)	47.4% (27.3 to 70.4)	22.3% (16.2 to 27.8)	176 (124 to 237)	89.2% (64.8 to 108)	22.2% (16.1 to 27.6)	97.3 (58.6 to 146)	16.1% (12.8 to 175)	22.5% (16.3 to 28.0)	79.0 (57.2 to 103)	41.2% (20.1 to 65.0)
South Asia	24.5% (17.6 to 31.4)	4.59 (3.24 to 5.98)	98.0% (39.5 to 149)	24.3% (17.5 to 31.2)	203 (140 to 275)	98.2% (42.0 to 134)	24.3% (17.4 to 31.2)	105 (64.2 to 155)	122% (59.0 to 149)	24.4% (17.6 to 31.2)	98.8 (70.3 to 129)	78.0% (24.8 to 127)
Southeast Asia, east Asia, and Oceania	21.6% (15.7 to 27.0)	4.05 (2.91 to 5.14)	89.5% (47.5 to 122)	21.8% (15.9 to 27.3)	187 (134 to 244)	87.8% (47.1 to 112)	22.3% (16.2 to 28.0)	97.3 (59.3 to 143)	110% (65.4 to 133)	21.3% (15.5 to 26.7)	89.9 (64.8 to 114)	68.4% (30.7 to 98.9)
Sub-Saharan Africa	24.4% (17.3 to 33.7)	3.51 (2.42 to 4.80)	-8.38% (-33.3 to 13.0)	24.2% (17.1 to 33.6)	122 (83.5 to 173)	-2.36% (-28.7 to 18.8)	24.1% (17.1 to 33.6)	40.8 (24.1 to 62.8)	30.5% (-2.38 to 48.3)	24.2% (17.1 to 33.5)	81.6 (56.1 to 112)	-13.3% (-37.2 to 9.10)

(Table continues on next page)


	Deaths				DALYs				YLDs				VLDs			
	Percentage (%)	Rate per 100 000	Percentage change (%)	Percentage (%)	Rate per 100 000	Percentage change (%)	Percentage (%)	Rate per 100 000	Percentage change (%)	Percentage (%)	Rate per 100 000	Percentage change (%)	Percentage (%)	Rate per 100 000	Percentage change (%)	
<i>(Continued from previous page)</i>																
<b>Ambient PM<sub>2.5</sub> pollution</b>																
Global	13.4% (9.49 to 17.5)	2.54 (1.76 to 3.34)	144% (104 to 196)	13.6% (9.73 to 17.9)	117 (79.3 to 158)	168% (126 to 225)	13.9% (9.94 to 18.1)	63.3 (37.3 to 70.1)	203% (157 to 269)	13.3% (9.47 to 17.4)	535 (314 to 613)	13.3% (9.47 to 17.4)	535 (314 to 613)	203% (157 to 269)	136% (96.9 to 186)	
Central Europe, eastern Europe, and central Asia	14.4% (9.83 to 19.2)	2.23 (1.52 to 3.01)	105% (58.5 to 180)	14.2% (9.73 to 19.0)	120 (75.9 to 172)	93.0% (52.2 to 161)	14.0% (9.54 to 18.8)	74.7 (42.2 to 114)	96.6% (55.5 to 167)	14.5% (10.0 to 19.4)	457 (31.4 to 455)	14.5% (10.0 to 19.4)	457 (31.4 to 455)	96.6% (55.5 to 167)	87.4% (45.1 to 145)	
High income	9.53% (5.71 to 14.3)	1.89 (1.13 to 2.82)	-16.7% (-40.1 to 20.8)	9.23% (5.44 to 14.0)	92.5 (51.9 to 148)	10.1% (-23.2 to 54.6)	9.20% (5.40 to 14.0)	63.4 (32.0 to 104)	46.4% (3.82 to 108)	9.29% (5.52 to 14.0)	290 (17.3 to 43.8)	9.29% (5.52 to 14.0)	290 (17.3 to 43.8)	46.4% (3.82 to 108)	-28.6% (-48.7 to 1.59)	
Latin America and Caribbean	12.1% (8.27 to 16.2)	4.12 (2.73 to 5.61)	124% (66.5 to 217)	12.2% (8.33 to 16.3)	166 (108 to 233)	129% (71.4 to 222)	12.2% (8.38 to 16.4)	78.0 (44.5 to 120)	177% (104 to 295)	12.1% (8.29 to 16.2)	87.7 (58.9 to 119)	12.1% (8.29 to 16.2)	87.7 (58.9 to 119)	177% (104 to 295)	98.8% (47.4 to 182)	
North Africa and Middle East	20.9% (15.2 to 26.2)	3.28 (2.36 to 4.22)	104% (71.7 to 151)	20.7% (15.0 to 25.9)	164 (117 to 220)	164% (127 to 215)	20.7% (15.0 to 26.0)	90.6 (54.3 to 136)	272% (229 to 339)	20.8% (15.2 to 26.0)	73.1 (52.9 to 94.9)	20.8% (15.2 to 26.0)	73.1 (52.9 to 94.9)	272% (229 to 339)	94.2% (62.8 to 141)	
South Asia	15.2% (10.5 to 20.5)	2.85 (1.90 to 3.88)	484% (250 to 1130)	15.2% (10.5 to 20.5)	128 (84.4 to 177)	471% (251 to 1070)	15.3% (10.5 to 20.5)	66.0 (38.1 to 102)	526% (292 to 1190)	15.2% (10.4 to 20.5)	61.6 (41.1 to 83.5)	15.2% (10.4 to 20.5)	61.6 (41.1 to 83.5)	526% (292 to 1190)	422% (212 to 1000)	
Southeast Asia, east Asia, and Oceania	14.3% (10.0 to 18.9)	2.69 (1.85 to 3.58)	357% (203 to 660)	15.2% (10.7 to 19.9)	130 (85.6 to 178)	359% (204 to 675)	16.5% (11.8 to 21.4)	71.9 (42.4 to 108)	423% (241 to 817)	13.8% (9.59 to 18.3)	583 (40.1 to 78.2)	13.8% (9.59 to 18.3)	583 (40.1 to 78.2)	423% (241 to 817)	298% (164 to 561)	
Sub-Saharan Africa	8.70% (5.62 to 12.5)	1.25 (0.792 to 1.80)	139% (74.1 to 231)	8.24% (5.25 to 11.9)	41.6 (26.5 to 61.2)	149% (84.0 to 243)	7.93% (4.98 to 11.5)	13.4 (7.43 to 21.0)	211% (132 to 324)	8.39% (5.36 to 12.1)	283 (17.8 to 41.6)	8.39% (5.36 to 12.1)	283 (17.8 to 41.6)	211% (132 to 324)	127% (65.7 to 216)	
<b>Household air pollution from solid fuels</b>																
Global	6.50% (4.22 to 9.53)	1.24 (0.782 to 1.79)	-11.5% (-35.6 to 12.5)	5.92% (3.81 to 8.64)	50.7 (31.4 to 75.6)	-13.3% (-35.9 to 10.5)	5.00% (3.16 to 7.44)	22.7 (12.2 to 37.6)	-6.79% (-30.5 to 17.8)	6.95% (4.51 to 10.1)	28.0 (17.6 to 40.7)	6.95% (4.51 to 10.1)	28.0 (17.6 to 40.7)	-6.79% (-30.5 to 17.8)	-17.9% (-40.0 to 4.07)	
Central Europe, eastern Europe, and central Asia	1.84% (0.794 to 3.55)	0.286 (0.121 to 0.544)	-31.2% (-56.8 to -2.18)	1.71% (0.721 to 3.36)	14.5 (5.83 to 29.1)	-34.5% (-58.3 to -7.33)	1.60% (0.66 to 3.26)	8.53 (3.20 to 18.7)	-32.2% (-57.9 to -3.14)	1.88% (0.815 to 3.61)	5.93 (2.55 to 11.2)	1.88% (0.815 to 3.61)	5.93 (2.55 to 11.2)	-32.2% (-57.9 to -3.14)	-37.5% (-59.4 to -12.2)	
High income	0.086% (0.028 to 0.212)	0.017 (0.006 to 0.041)	-79.8% (-88.0 to -70.0)	0.072% (0.023 to 0.180)	0.724 (0.224 to 1.77)	-74.7% (-85.0 to -62.5)	0.065% (0.020 to 0.161)	0.449 (0.129 to 1.12)	-65.2% (-79.1 to -48.2)	0.088% (0.029 to 0.217)	0.275 (0.091 to 0.668)	0.088% (0.029 to 0.217)	0.275 (0.091 to 0.668)	-65.2% (-79.1 to -48.2)	-82.6% (-89.7 to -73.9)	
Latin America and Caribbean	3.93% (2.38 to 6.01)	1.34 (0.789 to 2.05)	-25.6% (-46.6 to -3.44)	3.84% (2.34 to 5.91)	52.3 (30.6 to 80.7)	-25.6% (-45.8 to -4.01)	3.62% (2.17 to 5.62)	23.1 (11.7 to 38.5)	-16.1% (-38.5 to 7.98)	4.04% (2.47 to 6.16)	29.2 (17.5 to 44.2)	4.04% (2.47 to 6.16)	29.2 (17.5 to 44.2)	-16.1% (-38.5 to 7.98)	-82.6% (-89.7 to -73.9)	
North Africa and Middle East	1.48% (0.860 to 2.35)	0.233 (0.135 to 0.382)	-69.9% (-78.7 to -59.1)	1.59% (0.971 to 2.42)	12.6 (7.42 to 19.7)	-59.7% (-67.7 to -49.3)	1.52% (0.939 to 2.22)	6.64 (3.48 to 11.1)	-48.3% (-56.8 to -38.8)	1.68% (0.969 to 2.75)	5.93 (3.35 to 10.0)	1.68% (0.969 to 2.75)	5.93 (3.35 to 10.0)	-48.3% (-56.8 to -38.8)	-67.6% (-77.7 to -55.4)	
South Asia	9.27% (5.75 to 13.8)	1.74 (1.07 to 2.65)	-5.06% (-38.1 to 32.9)	9.07% (5.60 to 13.6)	75.9 (44.9 to 118)	-5.54% (-36.9 to 30.2)	8.95% (5.56 to 13.4)	38.7 (20.2 to 63.3)	5.58% (-28.5 to 43.5)	9.19% (5.68 to 13.7)	372 (22.9 to 56.2)	9.19% (5.68 to 13.7)	372 (22.9 to 56.2)	5.58% (-28.5 to 43.5)	-14.8% (-44.8 to 20.1)	
Southeast Asia, east Asia, and Oceania	7.25% (4.27 to 11.0)	1.36 (0.803 to 2.07)	-12.1% (-40.7 to 22.9)	6.64% (3.86 to 10.2)	57.0 (32.3 to 89.5)	-20.1% (-47.1 to 10.9)	5.82% (3.31 to 9.24)	25.4 (12.5 to 43.8)	-22.1% (-50.6 to 11.1)	7.48% (4.45 to 11.3)	31.6 (18.6 to 48.1)	7.48% (4.45 to 11.3)	31.6 (18.6 to 48.1)	-22.1% (-50.6 to 11.1)	-18.4% (-44.8 to 13.2)	
Sub-Saharan Africa	15.7% (10.7 to 23.9)	2.26 (1.48 to 3.41)	-31.6% (-49.8 to -13.5)	16.0% (10.8 to 24.3)	80.8 (52.0 to 125)	-25.6% (-45.6 to -6.84)	16.2% (11.0 to 24.6)	27.4 (15.3 to 45.0)	1.65% (-23.1 to 20.3)	15.8% (10.7 to 24.1)	53.4 (34.6 to 80.6)	15.8% (10.7 to 24.1)	53.4 (34.6 to 80.6)	1.65% (-23.1 to 20.3)	-34.6% (-52.8 to -15.6)	

Data in parentheses are 95% uncertainty intervals. Data are presented to three significant figures. DALYs=disability-adjusted life-years; GBD=Global Burden of Diseases, Injuries, and Risk Factors Study; PM=particulate matter; YLDs=years lived with disability; YLLs=years of life lost.

**Table: Type 2 diabetes deaths, DALYs, YLDs, and VLDs attributable to all PM<sub>2.5</sub> air pollution, ambient PM<sub>2.5</sub> pollution, and household PM<sub>2.5</sub> pollution from solid fuels in seven GBD super-regions and globally in 2019, and change from 1990 to 2019**



(Figure 2 continues on next page)



**Figure 2: Spatial distribution of the PAF of type 2 diabetes DALYs at all ages and in both sexes attributable to  $PM_{2.5}$  air pollution, 2019**


Maps show the PAF of type 2 diabetes DALYs at all ages and in both sexes in 2019 that was due to  $PM_{2.5}$  air pollution (A), ambient  $PM_{2.5}$  pollution (B), and household air pollution from solid fuels (C). DALYs=disability-adjusted life-years. PAF=population attributable fraction. PM=particulate matter.

global burden of type 2 diabetes was attributable to air pollution, with 13.4% from ambient  $PM_{2.5}$  and 6.5% from household air pollution. At the population level, air pollution was responsible for more attributable burden than either tobacco or physical inactivity.<sup>17</sup> Combining the exposure–response relationship with global location-specific exposure data revealed a geographically explicit pattern. Africa, Asia, and South America in particular showed a high burden attributable to air pollution. In most areas, with the exception of sub-Saharan Africa, this burden was dominated by ambient  $PM_{2.5}$ , whereas household air pollution played only a minor part. Over the past three decades, absolute DALYs and DALY rates attributable to  $PM_{2.5}$  pollution have considerably increased. Our decomposition analysis showed that in most regions, improvements in household air pollution were counterbalanced by increased ambient air pollution. In addition to increased ambient air pollution exposure, population growth and ageing contributed to the large increase in the type 2 diabetes burden attributable to air pollution.

Our study relied on an extensive number of studies and effect estimates that were combined and integrated across the exposure ranges. Based on the exposure–response curve, we estimated the attributable burden for ambient air pollution and household air pollution from

1990 to 2019 and did a decomposition analysis. Despite these obvious strengths, there are several limitations, and causality and confounding especially need to be addressed. Although cohort and case-control studies, the two types of epidemiological studies compiled for this research, rank at the upper end of the epidemiological evidence hierarchy, they are by no means proof of causality. Studies assessing the relationship between air pollution and type 2 diabetes consistently revealed increased incidence and prevalence. Most of the studies adjusted for personal-level confounders such as age and sex. Some, but not all, studies adjusted for socioeconomic status (eg, income, education and body-mass index) and behaviour (eg, smoking, alcohol use, and physical activity). Several studies have suggested that the effect of air pollution on type 2 diabetes varied over different groups. Honda and colleagues<sup>19</sup> found increased risk in a cohort of older people (age  $\geq 57$  years), and other studies particularly highlighted women as more vulnerable.<sup>20</sup> Park and colleagues<sup>20</sup> emphasised the likeliness of different population groups and ethnicities exhibiting different risks. Similarly, other forms of ambient air pollution not considered in our and other studies, such as gaseous pollutants, might also be relevant. Some evidence suggests that traffic-related air pollution is a higher risk for type 2 diabetes.<sup>21–23</sup> Several studies have






**Figure 3: Temporal trend in the type 2 diabetes burden attributable to air pollution, ambient particulate matter pollution, and household air pollution from solid fuels, 1990–2019**

Data are for all ages and both sexes by GBD super-region and globally. DALYs=disability-adjusted life-years. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. PAF=population attributable fraction. PM=particulate matter.

found a consistent effect of nitrogen dioxide on type 2 diabetes incidence, but this effect is less consistent for PM.<sup>7,24</sup> However, few studies adjust for nitrogen dioxide or noise, which are often correlated.<sup>25</sup>

The exposure–response relationship sharply increases from the theoretical minimum risk exposure level to approximately 50 µg/m<sup>3</sup> and levels off throughout the exposure range. Although the shape fits the data well, the constraints and priors imposed on the fit enable this shape. Specifically, we included shape priors so that the curve would be monotonically increasing and concave. Furthermore, a strong prior on the upper segment prevented the curve from strongly increasing beyond the exposure range for which effect estimates were available. The shape of our derived exposure–response curve, which reflects a strong increase at lower exposures and a levelling off at higher air pollution levels, has been found in other studies, such as the hazard curve developed from the US Veterans Cohort data.<sup>26</sup> This suggests the possibility of saturation of the mechanism (or mechanisms) driving the biological connection between PM exposure and type 2 diabetes, as has been postulated for cardiovascular mortality.<sup>27,28</sup> Indeed, the same non-linearity has been reported for cardiovascular mortality in the Canadian Census and cohort studies in males in China.<sup>24,29</sup> In addition to saturation, changes in the aerosol composition might be driving this shape. The issue of equitoxicity has



**Figure 4: Drivers of trends in type 2 diabetes DALYs attributable to air pollution in GBD super-regions and globally, 1990–2019**

Data are for all ages and both sexes. The PM<sub>2.5</sub> pollution-deleted DALY rate is the expected rate if air pollution were reduced to the theoretical minimum risk exposure level and captures changes in other risk factors or treatment practices. DALYs=disability-adjusted life-years. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. PM=particulate matter.

frequently been raised within the scientific community. Although differing toxicity is plausible, so far, PM<sub>2.5</sub> has proved to be the most consistent and robust predictor of mortality in studies of long-term exposure.<sup>30–32</sup>

In summary, the relationship between air pollution and type 2 diabetes is highly complex, and effect estimations are strongly affected by study design, cohort characteristics, the degree of covariate adjustment, and exposure assessment. Although our meta-regression framework cannot fully overcome all limitations in the original study designs, the MR-BRT tool allowed us to account for several study-level covariates and remaining between-study heterogeneity. The exposure–response relationship was significant along the entire range of exposures. In conjunction with the biological plausibility of an effect of PM inhalation on type 2 diabetes, we considered the evidence sufficient to include PM<sub>2.5</sub> and type 2 diabetes as a new risk–outcome pair into the GBD. Our results highlight the relevance of air pollution as a risk factor for type 2 diabetes. The attributable burden shows strong regional variation and distinct temporal trends: although ambient air pollution contributes a larger share globally, in sub-Saharan Africa, a larger part can be attributed to household air pollution. In almost all GBD super-regions, except the high-income region, the burden attributable to ambient air pollution has increased, whereas the burden attributable to household air pollution has decreased globally and in all regions.

#### GBD 2019 Diabetes and Air Pollution Collaborators

Katrin Burkart, Kate Causey, Aaron J Cohen, Sarah S Wozniak, Devashri Digvijay Salvi, Cristiana Abbafati, Victor Adekanmbi, Jose C Adsuar, Keivan Ahmadi, Fares Alahdab, Ziyad Al-Aly, Vahid Alipour, Nelson Alvis-Guzman, Adeladza Kofi Amegah, Catalina Liliana Andrei, Tudorel Andrei, Fereshteh Ansari, Jalal Arabloo, Olatunde Aremu, Timur Aripov, Ebrahim Babae, Maciej Banach, Anthony Barnett, Till Winfried Bärnighausen, Neeraj Bedi, Masoud Behzadifar, Yannick Béjot, Derrick A Bennett, Isabela M Bensenor, Robert S Bernstein, Kritika Bhattacharyya, Ali Bijani, Antonio Biondi, Somayeh Bohlouli, Susanne Breitner, Hermann Brenner, Zahid A Butt, Luis Alberto Cámara, Carlos Cantu-Brito, Felix Carvalho, Ester Cerin, Vijay Kumar Chattu, Bal Govind Chauhan, Jee-Young Jasmine Choi, Dinh-Toi Chu, Xiaochen Dai, Lalit Dandona, Rakhi Dandona, Ahmad Daryani, Kairat Davletov, Barbora de Courten, Feleke Mekonnen Demeke, Edgar Denova-Gutiérrez, Samath Dhamminda Dharmaratne, Meghnath Dhimal, Daniel Diaz, Shirin Djalalinia, Bruce B Duncan, Maysaa El Sayed Zaki, Sharareh Eskandarieh, Mohammad Fareed, Farshad Farzadfar, Nazir Fattahi, Mehdi Fazlzadeh, Eduarda Fernandes, Irina Filip, Florian Fischer, Nataliya A Foigt, Marisa Freitas, Ahmad Ghashghaee, Paramjit Singh Gill, Ibrahim Abdelmageed Ginawi, Sameer Vali Gopalani, Yuming Guo, Rajat Das Gupta, Tesfa Dejenie Habtewold, Randah R Hamadeh, Samer Hamidi, Graeme J Hankey, Edris Hasanpoor, Hamid Yimam Hassen, Simon I Hay, Behzad Heibati, Michael K Hole, Naznin Hossain, Mowafa Househ, Seyed Sina Naghibi Irvani, Jalil Jaafari, Mihajlo Jakovljevic, Ravi Prakash Jha, Jost B Jonas, Jacek Jerzy Jozwiak, Amir Kasaeian, Neda Kaydi, Yousef Saleh Khader, Morteza Abdullatif Khafaie, Ejaz Ahmad Khan, Junaid Khan, Md Nuruzzaman Khan, Khaled Khatab, Amir M Khater, Yun Jin Kim, Ruth W Kimokoti, Adnan Kisa, Mika Kivimäki, Luke D Knibbs, Soewarta Kosen, Parvaiz A Koul, Ai Koyanagi, Barthelemy Kuate Defo, Nuworza Kugbey, Paolo Lauriola, Paul H Lee, Mostafa Leili, Sonia Lewycka, Shanshan Li, Lee-Ling Lim, Shai Linn, Yong Liu, Stefan Lorkowski, Phetole Walter Mahasha, Narayan B Mahotra, Azeem Majeed, Afshin Maleki, Reza Malekzadeh, Abdullah A Mamun, Navid Manafi, Santi Martini, Birhanu Geta Meharie,

Ritesh G Menezes, Tomislav Mestrovic, Bartosz Miazgowski, Tomasz Miazgowski, Ted R Miller, GK Mini, Andreea Mirica, Erkin M Mirrakhimov, Bahram Mohajer, Shafiu Mohammed, Viswanathan Mohan, Ali H Mokdad, Lorenzo Monasta, Paula Moraga, Shane Douglas Morrison, Ulrich Otto Mueller, Satinath Mukhopadhyay, Ghulam Mustafa, Saravanan Muthupandian, Gurudatta Naik, Vinay Nangia, Duduzile Edith Ndwandwe, Ruxandra Irina Negoii, Dina Nur Anggraini Ningrum, Jean Jacques Noubiay, Felix Akpojene Ogbo, Andrew T Olagunju, Obinna E Onwujekwe, Alberto Ortiz, Mayowa O Owolabi, Mahesh P A, Songhomitra Panda-Jonas, Eun-Kee Park, Fatemeh Pashazadeh Kan, Meghdad Pirsaeheb, Maarten J Postma, Hadi Pourjafar, Amir Radfar, Alireza Rafiei, Fakher Rahim, Vafa Rahimi-Movaghar, Muhammad Aziz Rahman, Rajesh Kumar Rai, Chhabi Lal Ranabhat, Samira Raofi, Lal Rawal, Andre M N Renzaho, Aziz Rezapour, Daniela Ribeiro, Leonardo Roever, Luca Ronfani, Siamak Sabour, Basema Saddik, Ehsan Sadeghi, Sahar Saeedi Moghaddam, Amirhossein Sahebkar, Mohammad Ali Sahraian, Hamideh Salimzadeh, Sundeep Santosh Salvi, Abdallah M Samy, Juan Sanabria, Rodrigo Sarmiento-Suárez, Thirunavukkarasu Sathish, Maria Inês Schmidt, Aletta Elisabeth Schutte, Sadaf G Sepanlou, Masood Ali Shaikh, Kiomars Sharafi, Aziz Sheikh, Mika Shigematsu, Rahman Shiri, Reza Shirkoobi, Kerem Shuval, Ireneous N Soyiri, Rafael Tabarés-Seisdedos, Yonatal Mesfin Tefera, Arash Tehrani-Banihashemi, Mohamad-Hani Temsah, Kavumpurathu Raman Thankappan, Roman Topor-Madry, Lorainne Tudor Car, Irfan Ullah, Marco Vacante, Pascual R Valdez, Tommi Juhani Vasankari, Francesco S Violante, Yasir Waheed, Charles D A Wolfe, Tomohide Yamada, Naohiro Yonemoto, Chuanhua Yu, Sojib Bin Zaman, Yunquan Zhang, Sanjay Zodpey, Stephen S Lim, Jeffrey D Stanaway, Michael Brauer.

#### Affiliations

Institute for Health Metrics and Evaluation (K Burkart PhD, A J Cohen DSc, S S Wozniak BA, X Dai PhD, Prof L Dandona MD, Prof R Dandona PhD, Prof S I Hay FMedSci, A H Mokdad PhD, Prof S S Lim PhD, J D Stanaway PhD, Prof M Brauer DSc), Department of Health Metrics Sciences, School of Medicine (K Burkart PhD, X Dai PhD, Prof S D Dharmaratne MD, Prof S I Hay FMedSci, A H Mokdad PhD, Prof S S Lim PhD, J D Stanaway PhD), Division of Plastic and Reconstructive Surgery (S D Morrison MD), University of Washington, Seattle, WA, USA; Research, Insights, and Innovation (K Causey MPH), Independent Consultant, Seattle, WA, USA; Health Effects Institute, Boston, MA, USA (A J Cohen DSc); School of Public Health (D Salvi MPH), Boston University, Boston, MA, USA; Department of Juridical and Economic Studies (C Abbafati PhD), La Sapienza University, Rome, Italy; Department of Population Medicine (V Adekanmbi PhD), Cardiff University, Cardiff, UK; Sport Science Department (J C Adsuar PhD), University of Extremadura, Badajoz, Spain; School of Public Health (K Ahmadi PhD), Department of Primary Care and Public Health (Prof A Majeed MD), Imperial College London, London, UK; Mayo Evidence-based Practice Center (F Alahdab MSc), Mayo Clinic Foundation for Medical Education and Research, Rochester, MN, USA; John T. Milliken Department of Internal Medicine (Z Al-Aly MD), Washington University in St. Louis, St. Louis, MO, USA; Clinical Epidemiology Center (Z Al-Aly MD), US Department of Veterans Affairs (VA), St Louis, MO, USA; Health Management and Economics Research Center (V Alipour PhD, J Arabloo PhD, A Rezapour PhD), Department of Health Economics (V Alipour PhD), Preventive Medicine and Public Health Research Center (E Babae PhD, A Tehrani-Banihashemi PhD), Pars Advanced and Minimally Invasive Medical Manners Research Center (A Kasaeian PhD), Department of Community and Family Medicine (A Tehrani-Banihashemi PhD), Iran University of Medical Sciences, Tehran, Iran (F Pashazadeh Kan BSN); Research Group in Hospital Management and Health Policies (Prof N Alvis-Guzman PhD), Universidad de la Costa (University of the Coast), Barranquilla, Colombia; Research Group in Health Economics (Prof N Alvis-Guzman PhD), University of Cartagena, Cartagena, Colombia; Department of Biomedical Science (A K Amegah PhD), University of Cape Coast, Cape Coast, Ghana; Cardiology Department (C Andrei PhD), Department of Anatomy and Embryology (R I Negoii PhD), Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Statistics and

Econometrics (Prof T Andrei PhD, A Mirica PhD), Bucharest University of Economic Studies, Bucharest, Romania; Research Center for Evidence Based Medicine (F Ansari PhD), Tabriz University of Medical Sciences, Tabriz, Iran; Razi Vaccine and Serum Research Institute (F Ansari PhD), Agricultural Research, Education, and Extension Organization (AREEO), Tehran, Iran; Department of Public Health (O Aremu PhD), Birmingham City University, Birmingham, UK; Public Health and Healthcare Management (T Aripov PhD), Tashkent Institute of Postgraduate Medical Education, Tashkent, Uzbekistan; Boston Children's Hospital, Boston, MA, USA (T Aripov PhD); Department of Hypertension (Prof M Banach PhD), Medical University of Lodz, Lodz, Poland; Polish Mothers' Memorial Hospital Research Institute, Lodz, Poland (Prof M Banach PhD); Mary MacKillop Institute for Health Research (A Barnett PhD, Prof E Cerin PhD), Australian Catholic University, Melbourne, VIC, Australia; Heidelberg Institute of Global Health (HIGH) (Prof T W Bärnighausen MD), Heidelberg University, Heidelberg, Germany; T.H. Chan School of Public Health (Prof T W Bärnighausen MD), Division of General Internal Medicine (Prof A Sheikh MD), Harvard University, Boston, MA, USA; School of Public Health (Prof N Bedi MD), Dr. D. Y. Patil University, Mumbai, India; Jazan University, Jazan, Saudi Arabia (Prof N Bedi MD); Social Determinants of Health Research Center (M Behzadifar PhD), Lorestan University of Medical Sciences, Khorramabad, Iran; Department of Neurology (Prof Y Béjot PhD), University Hospital of Dijon, Dijon, France; Dijon Stroke Registry - UFR Sciences Santé (Prof Y Béjot PhD), University of Burgundy, Dijon, France; Nuffield Department of Population Health (D A Bennett PhD), Centre for Tropical Medicine and Global Health (S Lewycka PhD), University of Oxford, Oxford, UK; Department of Internal Medicine (I M Bensenor PhD), University of São Paulo, São Paulo, Brazil; Hubert Department of Global Health (R S Bernstein MD), Emory University, Atlanta, GA, USA; Butte County Department of Public Health, Chico, CA, USA (R S Bernstein MD); Department of Statistical and Computational Genomics (K Bhattacharyya MSc), National Institute of Biomedical Genomics, Kalyani, India; Department of Statistics (K Bhattacharyya MSc), University of Calcutta, Kolkata, India; Social Determinants of Health Research Center (A Bijani PhD), Babol University of Medical Sciences, Babol, Iran; Department of General Surgery and Medical-Surgical Specialties (Prof A Biondi PhD, M Vacante PhD), University of Catania, Catania, Italy; Department of Veterinary Medicine (S Bohlouli PhD), Islamic Azad University, Kermanshah, Iran; Institute for Medical Information Processing, Biometry, and Epidemiology (S Breitrner DSc), Ludwig Maximilian University of Munich, Munich, Germany; Institute of Epidemiology (S Breitrner DSc), German Research Center for Environmental Health, Neuherberg, Germany; Division of Clinical Epidemiology and Aging Research (Prof H Brenner MD), German Cancer Research Center, Heidelberg, Germany; School of Public Health and Health Systems (Z A Butt PhD), University of Waterloo, Waterloo, ON, Canada; Al Shifa School of Public Health (Z A Butt PhD), Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan; Internal Medicine Department (Prof L A Cámara MD), Hospital Italiano de Buenos Aires (Italian Hospital of Buenos Aires), Buenos Aires, Argentina; Board of Directors (Prof L A Cámara MD), Argentine Society of Medicine, Buenos Aires, Argentina (Prof P R Valdez M.Ed.); Department of Neurology (Prof C Cantu-Brito PhD), Salvador Zubiran National Institute of Medical Sciences and Nutrition, Mexico City, Mexico; Research Unit on Applied Molecular Biosciences (UCIBIO) (Prof F Carvalho PhD), Associated Laboratory for Green Chemistry (LAQV) (Prof E Fernandes PhD, M Freitas PhD, D Ribeiro PhD), University of Porto, Porto, Portugal; School of Public Health (Prof E Cerin PhD), University of Hong Kong, Hong Kong, China; Department of Community Medicine (V Chattu MD), Datta Meghe Institute of Medical Sciences, Sawangi, India; Saveetha Medical College (V Chattu MD), Saveetha University, Chennai, India; Population Research Centre (B Chauhan MPhil), Gokhale Institute of Politics and Economics, Pune, India; Department of Population Studies (J Khan PhD), International Institute for Population Sciences, Mumbai, India (B Chauhan MPhil); Division of Biomedical Informatics (J J Choi PhD), Seoul National University Hospital, Seoul, South Korea; Center for Biomedicine and Community Health (D Chu PhD), VNU-International School, Hanoi, Vietnam; Indian Institute of Public Health (Prof S Zodpey PhD), Public Health Foundation of India, Gurugram, India (Prof L Dandona MD, Prof R Dandona PhD); Indian Council of Medical Research, New Delhi, India (Prof L Dandona MD); Department of Health Metrics Sciences, School of Medicine (Prof R Dandona PhD), Institute for Health Metrics and Evaluation (Prof S D Dharmaratne MD), University of Washington, Seattle, WA, United States; Toxoplasmosis Research Center (Prof A Daryani PhD), Department of Immunology (Prof A Rafiei PhD), Molecular and Cell Biology Research Center (Prof A Rafiei PhD), Mazandaran University of Medical Sciences, Sari, Iran; Health Research Institute (K Davletov PhD), Al Farabi Kazakh National University, Almaty, Kazakhstan; The School of Clinical Sciences at Monash Health (Prof B de Courten PhD, S Zaman MPH), Department of Epidemiology and Preventive Medicine (Prof Y Guo PhD), School of Public Health and Preventive Medicine (S Li PhD), Monash University, Melbourne, VIC, Australia; Department of Medical Laboratory Sciences (F M Demeke MSc), Bahir Dar University, Bahir Dar, Ethiopia; Center for Nutrition and Health Research (E Denova-Gutiérrez DSc), National Institute of Public Health, Cuernavaca, Mexico; Department of Community Medicine (Prof S D Dharmaratne MD), University of Peradeniya, Peradeniya, Sri Lanka; Health Research Section (M Dhimal PhD), Nepal Health Research Council, Kathmandu, Nepal; Center of Complexity Sciences (Prof D Diaz PhD), National Autonomous University of Mexico, Mexico City, Mexico; Faculty of Veterinary Medicine and Zootechnics (Prof D Diaz PhD), Autonomous University of Sinaloa, Culiacán Rosales, Mexico; Development of Research and Technology Center (S Djalalinia PhD), Ministry of Health and Medical Education, Tehran, Iran; Postgraduate Program in Epidemiology (Prof B B Duncan MD, Prof M I Schmidt MD), Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Reference Laboratory of Egyptian Universities-Cairo (Prof M El Sayed Zaki PhD), Ministry of Higher Education and Scientific Research, Cairo, Egypt; Multiple Sclerosis Research Center (S Eskandarieh PhD, Prof M Sahraian MD), Non-communicable Diseases Research Center (Prof F Farzadfar DSc, B Mohajer MD, S Saeedi Moghaddam MSc), Department of Environmental Health Engineering (M Fazlzadeh PhD, Prof A Maleki PhD), Hematology, Oncology and Stem Cell Transplantation Research Center (A Kasaeian PhD), Digestive Diseases Research Institute (Prof R Malekzadeh MD, H Salimzadeh PhD, S G Sepanlou MD), Metabolomics and Genomics Research Center (F Rahim PhD), Sina Trauma and Surgery Research Center (Prof V Rahimi-Movaghgar MD), Cancer Research Center (R Shirkoobi PhD), Cancer Biology Research Center (R Shirkoobi PhD), Tehran University of Medical Sciences, Tehran, Iran; College of Medicine (M Fareed PhD), Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia; Research Center for Environmental Determinants of Health (N Fattahi PhD, Prof M Pirsaeheb PhD, Prof E Sadeghi PhD, K Sharafi PhD), Kermanshah University of Medical Sciences, Kermanshah, Iran; Department of Environmental Health Engineering (M Fazlzadeh PhD), Ardebil University of Medical Science, Ardebil, Iran; Psychiatry Department (I Filip MD), Kaiser Permanente, Fontana, CA, USA; School of Health Sciences (I Filip MD), A.T. Still University, Mesa, AZ, USA; Institute of Public Health (F Fischer PhD), Charité Universitätsmedizin Berlin (Charité Medical University Berlin), Berlin, Germany; Institute of Gerontology (N A Foigt PhD), National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; School of Public Health (A Ghashghaee BSc), Qazvin University of Medical Sciences, Qazvin, Iran; Warwick Medical School (Prof P S Gill DM), University of Warwick, Coventry, UK; Family Medicine Research Center (Prof I A Ginawi MD), Ministry of Health, Hail, Saudi Arabia; Hudson College of Public Health (S V Gopalani MPH), University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Department of Health and Social Affairs (S V Gopalani MPH), Government of the Federated States of Micronesia, Palikir, Federated States of Micronesia; Department of Epidemiology (Prof Y Guo PhD), Binzhou Medical University, Yantai City, China; Department of Epidemiology and Biostatistics (R Gupta MPH), University of South Carolina, Columbia, SC, USA; Centre for Non-communicable Diseases and Nutrition (R Gupta MPH), BRAC University, Dhaka, Bangladesh; Department of Quantitative Economics (T D Habtewold PhD), Maastricht University, Maastricht, Netherlands; Department of Family and Community Medicine (Prof R R Hamadeh PhD), Arabian Gulf University, Manama, Bahrain;

School of Health and Environmental Studies (Prof S Hamidi DrPH), Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates; Medical School (Prof G J Hankey MD), University of Western Australia, Perth, WA, Australia; Department of Neurology (Prof G J Hankey MD), Sir Charles Gairdner Hospital, Perth, WA, Australia; Department of Healthcare Management (E Hasanpoor PhD), Department of Nutrition and Food Sciences (H Pourjafar PhD), Maragheh University of Medical Sciences, Maragheh, Iran; Department of Primary and Interdisciplinary Care (H Y Hassen MPH), University Hospital Antwerp, Antwerp, Belgium; Department of Public Health (H Y Hassen MPH), Mizan-Tepi University, Mizan Teferi, Ethiopia; Center for Environmental and Respiratory Health Research (B Heibati PhD), University of Oulu, Oulu, Finland; Department of Pediatrics (M K Hole MD), University of Texas Austin, Austin, TX, USA; Department of Pharmacology (N Hossain MPhil), Bangladesh Industrial Gases Limited, Tangail, Bangladesh; College of Science and Engineering (Prof M Househ PhD), Hamad Bin Khalifa University, Doha, Qatar; Independent Consultant, Tabriz, Iran (S N Irvani MD); Department of Environmental Health Engineering (J Jaafari PhD), Guilan University of Medical Sciences, Rasht, Iran; Institute of Advanced Manufacturing Technologies (Prof M Jakovljevic PhD), Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russia; Institute of Comparative Economic Studies (Prof M Jakovljevic PhD), Hosei University, Tokyo, Japan; Department of Community Medicine (R P Jha MSc), Dr Baba Saheb Ambedkar Medical College & Hospital, Delhi, India; Department of Community Medicine (R P Jha MSc), Banaras Hindu University, Varanasi, India; Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland (Prof J B Jonas MD); Department of Ophthalmology (Prof J B Jonas MD), Heidelberg University, Mannheim, Germany; Department of Family Medicine and Public Health (J J Jozwiak PhD), University of Opole, Opole, Poland; Environmental Health Department (N Kaydi PhD), Social Determinants of Health Research Center (M A Khafaie PhD), Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Department of Public Health (Prof Y S Khader PhD), Jordan University of Science and Technology, Irbid, Jordan; Department of Epidemiology and Biostatistics (E A Khan MPH), Health Services Academy, Islamabad, Pakistan; Department of Population Science (M Khan PhD), Jatiya Kabi Kazi Nazrul Islam University, Mymensingh, Bangladesh; Faculty of Health and Wellbeing (K Khatab PhD), Sheffield Hallam University, Sheffield, UK; College of Arts and Sciences (K Khatab PhD), Ohio University, Zanesville, OH, USA; National Hepatology and Tropical Medicine Research Institute (A M Khater MD), Cairo University, Cairo, Egypt; School of Traditional Chinese Medicine (Y Kim PhD), Xiamen University Malaysia, Sepang, Malaysia; Department of Nutrition (R W Kimokoti MD), Simmons University, Boston, MA, USA; School of Health Sciences (Prof A Kisa PhD), Kristiania University College, Oslo, Norway; Department of Global Community Health and Behavioral Sciences (Prof A Kisa PhD), Tulane University, New Orleans, LA, USA; Department of Epidemiology and Public Health (Prof M Kivimäki PhD), University College London, London, UK; Department of Public Health (Prof M Kivimäki PhD), University of Helsinki, Helsinki, Finland; School of Public Health (L D Knibbs PhD), The University of Queensland, Herston, QLD, Australia; Independent Consultant, Jakarta, Indonesia (S Kosen MD); Department of Internal and Pulmonary Medicine (Prof P A Koul MD), Sheri Kashmir Institute of Medical Sciences, Srinagar, India; Biomedical Research Networking Center for Mental Health Network (CIBERSAM) (A Koyanagi MD), San Juan de Dios Sanitary Park, Sant Boi de Llobregat, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain (A Koyanagi MD); Department of Demography (Prof B Kuate Defo PhD), Department of Social and Preventive Medicine (Prof B Kuate Defo PhD), University of Montreal, Montreal, QC, Canada; University of Environment and Sustainable Development, Somanya, Ghana (N Kugbey PhD); International Society Doctors for the Environment, Arezzo, Italy (P Lauriola MD); Department of Health Sciences (P H Lee PhD), University of Leicester, Leicester, UK; Department of Environmental Health Engineering (M Leili PhD), Hamadan University of Medical Sciences, Hamadan, Iran; Oxford University Clinical Research Unit (S Lewycka PhD), Wellcome Trust Asia Programme, Hanoi, Vietnam; Department of Medicine (L Lim MRCP), University of Malaya, Kuala Lumpur, Malaysia; Department of Medicine and Therapeutics (L Lim MRCP), The Chinese University of Hong Kong, Shatin, China; School of Public Health (Prof S Linn DrPH, K Shuval PhD), University of Haifa, Haifa, Israel; Guangdong Provincial People's Hospital (Prof Y Liu PhD), Guangdong Academy of Medical Sciences and General Hospital, Guangzhou, China; Guangdong Provincial People's Hospital (Prof Y Liu PhD), Southern University of Science and Technology, Guangzhou, China; Institute of Nutritional Sciences (Prof S Lorkowski PhD), Friedrich Schiller University Jena, Jena, Germany; Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD), Jena, Germany (Prof S Lorkowski PhD); Grants, Innovation and Product Development Unit (P W Mahasha PhD), Cochrane South Africa (D E Ndwandwe PhD), South African Medical Research Council, Cape Town, South Africa; Department of Clinical Physiology (N B Mahotra MD), Tribhuvan University, Kathmandu, Nepal; Environmental Health Research Center (Prof A Maleki PhD), Kurdistan University of Medical Sciences, Sanandaj, Iran; Non-communicable Disease Research Center (Prof R Malekzadeh MD, S G Sepanlou MD), Shiraz University of Medical Sciences, Shiraz, Iran; Institute for Social Science Research (A A Mamun PhD), The University of Queensland, Indooroopilly, QLD, Australia; Doheny Eye Institute (N Manafi MD), University of California Los Angeles, Los Angeles, CA, USA; Faculty of Public Health (S Martini PhD), Universitas Airlangga (Airlangga University), Surabaya, Indonesia; Indonesian Public Health Association, Surabaya, Indonesia (S Martini PhD); Department of Pharmacy (B Meharie MSc), Department of Environmental Health (Y M Tefera MSc), Wollo University, Dessie, Ethiopia; Forensic Medicine Division (Prof R G Menezes MD), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; Clinical Microbiology and Parasitology Unit (T Mestrovic PhD), Dr. Zora Profozic Polyclinic, Zagreb, Croatia; University Centre Varazdin (T Mestrovic PhD), University North, Varazdin, Croatia; Center for Innovation in Medical Education (B Miazgowski MD), Department of Propedeutics of Internal Diseases & Arterial Hypertension (Prof T Miazgowski MD), Pomeranian Medical University, Szczecin, Poland (B Miazgowski MD); Pacific Institute for Research & Evaluation, Calverton, MD, USA (T R Miller PhD); School of Public Health (T R Miller PhD), Curtin University, Perth, WA, Australia; Global Institute of Public Health (Prof G Mini PhD), Ananthapuri Hospitals and Research Institute, Trivandrum, India; Women's Social and Health Studies Foundation, Trivandrum, India (Prof G Mini PhD); Internal Medicine Programme (Prof E M Mirrakhimov PhD), Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan; Department of Atherosclerosis and Coronary Heart Disease (Prof E M Mirrakhimov PhD), National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan; Health Systems and Policy Research Unit (S Mohammed PhD), Ahmadu Bello University, Zaria, Nigeria; Department of Health Care Management (S Mohammed PhD), Technical University of Berlin, Berlin, Germany; Department of Diabetology (V Mohan DSc), Madras Diabetes Research Foundation, Chennai, India; Department of Diabetology (V Mohan DSc), Dr. Mohan's Diabetes Specialities Centre, Chennai, India; Clinical Epidemiology and Public Health Research Unit (L Monasta DSc, L Ronfani PhD), Burlo Garofolo Institute for Maternal and Child Health, Trieste, Italy; Computer, Electrical, and Mathematical Sciences and Engineering Division (P Moraga PhD), King Abdullah University of Science and Technology, Thuwal, Saudi Arabia; Federal Institute for Population Research, Wiesbaden, Germany (Prof U O Mueller MD); Center for Population and Health, Wiesbaden, Germany (Prof U O Mueller MD); Department of Endocrinology & Metabolism (Prof S Mukhopadhyay MD), Institute of Post-Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital, Kolkata, India; Department of Pediatric Medicine (Prof G Mustafa MD), The Children's Hospital & The Institute of Child Health, Multan, Pakistan; Department of Pediatrics & Pediatric Pulmonology (Prof G Mustafa MD), Institute of Mother & Child Care, Multan, Pakistan; Department of Medical Microbiology and Immunology (S Muthupandian PhD), Mekelle University, Mekelle, Ethiopia; Saveetha Dental College (S Muthupandian PhD), Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India; Comprehensive Cancer Center (G Naik MPH), University of Alabama at Birmingham, Birmingham, AL, USA; Suraj Eye Institute, Nagpur, India (V Nangia MD); Cardio-Aid, Bucharest, Romania (R I Negoii PhD); Public Health

Department (D N A Ningrum MPH), Universitas Negeri Semarang (State University of Semarang), Kota Semarang, Indonesia; Graduate Institute of Biomedical Informatics (D N A Ningrum MPH), Taipei Medical University, Taipei, Taiwan; Centre for Heart Rhythm Disorders (J Noubiap MD), School of Public Health (Y M Tefera MSc), University of Adelaide, Adelaide, SA, Australia; Translational Health Research Institute (F A Ogbo PhD), Western Sydney University, Sydney, NSW, Australia; Department of Psychiatry and Behavioural Neurosciences (A T Olagunju MD), Population Health Research Institute (T Sathish PhD), McMaster University, Hamilton, ON, Canada; Department of Psychiatry (A T Olagunju MD), University of Lagos, Lagos, Nigeria; Department of Pharmacology and Therapeutics (Prof O E Onwujekwe PhD), University of Nigeria Nsukka, Enugu, Nigeria; Department of Medicine (Prof A Ortiz MD), Autonomous University of Madrid, Madrid, Spain; Department of Nephrology and Hypertension (Prof A Ortiz MD), The Institute for Health Research Foundation Jiménez Díaz University Hospital, Madrid, Spain; Department of Medicine (Prof M O Owolabi DrM), University of Ibadan, Ibadan, Nigeria; Department of Medicine (Prof M O Owolabi DrM), University College Hospital, Ibadan, Ibadan, Nigeria; Department of Respiratory Medicine (Prof M P A DNB), Jagadguru Sri Shivarathreeswara Academy of Health Education and Research, Mysore, India; Privatpraxis, Heidelberg, Germany (S Panda-Jonas MD); Department of Medical Humanities and Social Medicine (Prof E Park PhD), Kosin University, Busan, South Korea; University Medical Center Groningen (Prof M J Postma PhD), School of Economics and Business (Prof M J Postma PhD), University of Groningen, Groningen, Netherlands; Dietary Supplements and Probiotic Research Center (H Pourjafar PhD), Alborz University of Medical Sciences, Karaj, Iran; College of Medicine (A Radfar MD), University of Central Florida, Orlando, FL, USA; School of Nursing and Healthcare Professions (M Rahman PhD), Federation University Australia, Berwick, VIC, Australia; School of Nursing and Midwifery (M Rahman PhD), La Trobe University, Melbourne, VIC, Australia; Society for Health and Demographic Surveillance, Suri, India (R Rai MPH); Department of Economics (R Rai MPH), University of Göttingen, Göttingen, Germany; Research Department (C L Ranabhat PhD), Policy Research Institute, Kathmandu, Nepal; Health and Public Policy Department (C L Ranabhat PhD), Global Center for Research and Development, Kathmandu, Nepal; Iran University of Medical Sciences (S Raofi PhD), Independent Consultant, Tehran, Iran; School of Health, Medical and Applied Sciences (L Rawal PhD), CQ University, Sydney, NSW, Australia; School of Medicine (Prof A M N Renzaho PhD), Translational Health Research Institute (Prof A M N Renzaho PhD), Western Sydney University, Campbelltown, NSW, Australia; Faculty of Agrarian Sciences and Environment (D Ribeiro PhD), University of the Azores, Angra do Heroísmo, Portugal; Department of Clinical Research (L Roeber PhD), Federal University of Uberlândia, Uberlândia, Brazil; Department of Epidemiology (S Sabour PhD), Shahid Beheshti University of Medical Sciences, Tehran, Iran; Sharjah Institute for Medical Research (B Saddik PhD), University of Sharjah, Sharjah, United Arab Emirates; Applied Biomedical Research Center (A Sahebkar PhD), Biotechnology Research Center (A Sahebkar PhD), Mashhad University of Medical Sciences, Mashhad, Iran; Clinical Research Division (Prof S S Salvi MD), Chest Research Foundation, Pune, India; Department of Entomology (A M Samy PhD), Ain Shams University, Cairo, Egypt; Department of Surgery (Prof J Sanabria MD), Marshall University, Huntington, WV, USA; Department of Nutrition and Preventive Medicine (Prof J Sanabria MD), Case Western Reserve University, Cleveland, OH, USA; Department of Health and Society, Faculty of Medicine (Prof R Sarmiento-Suárez MPH), University of Applied and Environmental Sciences, Bogota, Colombia; National School of Public Health (Prof R Sarmiento-Suárez MPH), Carlos III Health Institute, Madrid, Spain; School of Public Health and Community Medicine (Prof A E Schutte PhD), University of New South Wales, Sydney, NSW, Australia; The George Institute for Global Health, Sydney, NSW, Australia (Prof A E Schutte PhD); Independent Consultant, Karachi, Pakistan (M A Shaikh MD); Centre for Medical Informatics (Prof A Sheikh MD), University of Edinburgh, Edinburgh, UK; National Institute of Infectious Diseases, Tokyo, Japan (M Shigematsu PhD); Finnish Institute of Occupational Health, Helsinki, Finland (R Shiri PhD); The Cooper Institute, Dallas, TX, USA (K Shuval PhD); Hull York Medical School (I N Soyiri PhD), University of

Hull, Hull City, UK; Department of Medicine (Prof R Tabarés-Seisdedos PhD), University of Valencia, Valencia, Spain; Carlos III Health Institute (Prof R Tabarés-Seisdedos PhD), Biomedical Research Networking Center for Mental Health Network (CiberSAM), Madrid, Spain; Pediatric Intensive Care Unit (M Tamsah MD), King Saud University, Riyadh, Saudi Arabia; Department of Public Health and Community Medicine (Prof K R Thankappan MD), Central University of Kerala, Kasaragod, India; Institute of Public Health (R Topor-Madry PhD), Jagiellonian University Medical College, Kraków, Poland; Agency for Health Technology Assessment and Tariff System, Warsaw, Poland (R Topor-Madry PhD); Lee Kong Chian School of Medicine (L Tudor Car PhD), Nanyang Technological University, Singapore, Singapore; Department of Life Sciences (I Ullah PhD), University of Management and Technology, Lahore, Pakistan; Pakistan Council for Science and Technology (I Ullah PhD), Ministry of Science and Technology, Islamabad, Pakistan; Velez Sarsfield Hospital, Buenos Aires, Argentina (Prof P R Valdez M.Ed.); UKK Institute, Tampere, Finland (Prof T J Vasankari MD); Faculty of Medicine and Health Technology (Prof T J Vasankari MD), Tampere University, Tampere, Finland; Department of Medical and Surgical Sciences (Prof F S Violante MD), University of Bologna, Bologna, Italy; Occupational Health Unit (Prof F S Violante MD), Sant'Orsola Malpighi Hospital, Bologna, Italy; Foundation University Medical College (Prof Y Waheed PhD), Foundation University Islamabad, Islamabad, Pakistan; School of Population Health and Environmental Sciences (Prof C D A Wolfe MD), King's College London, London, UK; NIHR Biomedical Research Centre (Prof C D A Wolfe MD), Guy's and St. Thomas' Hospital and Kings College London, London, UK; Department of Diabetes and Metabolic Diseases (T Yamada MD), University of Tokyo, Tokyo, Japan; Department of Neuropsychopharmacology (N Yonemoto PhD), National Center of Neurology and Psychiatry, Kodaira, Japan; Department of Public Health (N Yonemoto PhD), Juntendo University, Tokyo, Japan; Department of Epidemiology and Biostatistics (Prof C Yu PhD), Wuhan University, Wuhan, China; Maternal and Child Health Division (S Zaman MPH), International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; School of Public Health (Y Zhang PhD), Hubei Province Key Laboratory of Occupational Hazard Identification and Control (Y Zhang PhD), Wuhan University of Science and Technology, Wuhan, China; School of Population and Public Health (Prof M Brauer DSc), University of British Columbia, Vancouver, BC, Canada.

#### Contributors

Please see appendix (pp 6–7) for more detailed information about individual author contributions to the research, divided into the following categories: managing the overall research enterprise; writing the first draft of the manuscript; primary responsibility for applying analytical methods to produce estimates; primary responsibility for seeking, cataloguing, extracting, or cleaning data; designing or coding figures and tables; providing data or critical feedback on data sources; developing methods or computational machinery; providing critical feedback on methods or results; drafting the manuscript or revising it critically for important intellectual content; and managing the estimation or publications process. Employees of and faculties at the Institute for Health Metrics and Evaluation had full access to and verified the underlying data used to generate estimates presented in this Article. All other authors had access to and reviewed estimates as part of the research evaluation process, which includes additional stages of internal Institute for Health Metrics and Evaluation and external formal collaborator review.

#### Declaration of interests

T W Bärnighausen reports support for the present manuscript from the Alexander von Humboldt Foundation, Wellcome Trust, German Research Foundation, and US National Institutes of Health (National Institute of Allergy and Infectious Diseases, National Institute on Aging, and Fogarty International Center), all paid to his institution. Y Béjot reports consulting fees from Novo Nordisk and honoraria for lectures from Medtronic, Boehringer Ingelheim, Pfizer, Bristol Myers Squibb (BMS), Servier Laboratories, and Amgen, all outside the submitted work. L A Cámara reports non-financial support for the present manuscript from Sociedad Argentina de Medicina and Hospital Italiano Buenos Aires. X Dai reports support for the present manuscript via salary from the

Institute for Health Metrics and Evaluation University of Washington. I Filip and A Radfar report support from Avicenna Medical and Clinical Research Institute, outside the submitted work. J J Jozwiak reports payment via personal fees for lectures, presentations, speaker's bureaus, manuscript writing or educational events from Teva Pharmaceuticals, Amgen, Synexus, Boehringer Ingelheim, Zentiva, and Sanofi, all outside the submitted work. M Kivimäki reports research grants to University College London (London, UK) from the Wellcome Trust (221854/Z/20/Z) and the UK Medical Research Council (MR/S011676/1), outside the submitted work. S Lorkowski reports (all outside the submitted work) grants or contracts paid to his institution from Akcea Therapeutics Germany; consulting fees from Danone, Novartis Pharma, Swedish Orphan Biovitrum (SOBI), and Upfield; payment or honoraria for lectures, presentations, speaker's bureaus, manuscript writing, or educational events from Akcea Therapeutics Germany, Amarin Germany, Amedes Holding, Amgen, Berlin-Chemie, Boehringer Ingelheim, Daiichi Sankyo Deutschland, Danone, Hubert Burda Media Holding, Janssen-Cilag, Lilly Deutschland, Novartis, Novo Nordisk, F Hoffmann-La Roche (Roche), Sanofi-Aventis, SYNLAB Holding Deutschland, and SYNLAB Akademie; support for attending meetings or travel from Amgen; and participation on a data safety monitoring board or advisory board for Akcea Therapeutics Germany, Amgen, Daiichi Sankyo Deutschland, Novartis, and Sanofi-Aventis. P W Mahasha reports (all outside the submitted work) participation on a data safety monitoring board or advisory board as a member of the Technical Advisory Panel to the Office of Health Standards Compliance and Health Ombud from Feb 12, 2020, to Feb 11, 2022, and leadership or fiduciary roles in boards, societies, committees, or advocacy groups, paid or unpaid, as a member of the Federation of Infectious Diseases Societies of Southern Africa since November, 2021; the EU-Africa PerMed Consortium from February, 2021, to January, 2025; the South African Society for Biochemistry and Molecular Biology since August, 2021; the International Society for Infectious Diseases since November, 2021; the South African Society of Microbiology since November, 2021; the COVID-19 Clinical Research Coalition since August, 2021; the Scholars Academic and Scientific Society since August, 2021; Cochrane International since October, 2019 (renewed on March 13, 2022); and the South African Council for Natural Scientific Professions since June, 2018. A Ortiz reports (all outside the submitted work) grants from Sanofi; consultancy or speaker fees or travel support from Advicenne, Astellas, AstraZeneca, Amicus, Amgen, Fresenius Medical Care, GlaxoSmithKline, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Idorsia, Chiesi, Otsuka, Novo-Nordisk, and Vifor Fresenius Medical Care Renal Pharma; is Director of the Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra AstraZeneca-UAM of chronic kidney disease and electrolytes; is the Editor-in-Chief for *Clinical Kidney Journal*; and reports a leadership or fiduciary role with the European Renal Association and Madrid Renal Association. P A Mahesh reports grants or contracts paid to his institution from the Government of India (Wellcome Trust/DBT team science grant), the US National Institutes of Health Global Infectious Diseases, and the Swedish Heart Lung Foundation, outside the submitted work. M J Postma reports grants paid to his institution from Boehringer Ingelheim and AstraZeneca, and stock or stock options in Health-Ecore (25%) and Pharmacoconomics Advice Groningen (100%), all outside the submitted work. J Sanabria reports a pending patent for pNaKüde, and leadership or fiduciary roles in boards, societies, committees, or advocacy groups, paid or unpaid with the Society for the Surgery of the Alimentary Tract, American Association for the Study of Liver Diseases, Society of University Surgeons, and American Society of Transplant Surgeons, all outside the submitted work. P R Valdez reports support for the present manuscript from Sociedad Argentina de Medicina and Hospital Velez Sarsfield Buenos Aires. All other authors declare no competing interests.

#### Data sharing

To download the data used in these analyses, please visit the Global Health Data Exchange GBD 2019 results website

#### Acknowledgments

This study is funded by the Bill & Melinda Gates Foundation.

Editorial note: The Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

#### References

- 1 WHO. Global report on diabetes. April 21, 2016. <https://www.who.int/publications/i/item/9789241565257> (accessed June 15, 2018).
- 2 American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2009; **32** (suppl 1): S62–67.
- 3 GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2018; **396**: 1204–22.
- 4 Hotamisligil GS. Inflammation and metabolic disorders. *Nature* 2006; **444**: 860–67.
- 5 Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. *Lancet* 2018; **392**: 2052–90.
- 6 Chen H, Burnett RT, Kwong JC, et al. Risk of incident diabetes in relation to long-term exposure to fine particulate matter in Ontario, Canada. *Environ Health Perspect* 2013; **121**: 804–10.
- 7 Balti EV, Echouffo-Tcheugui JB, Yako YY, Kengne AP. Air pollution and risk of type 2 diabetes mellitus: a systematic review and meta-analysis. *Diabetes Res Clin Pract* 2014; **106**: 161–72.
- 8 Newby DE, Mannucci PM, Tell GS, et al. Expert position paper on air pollution and cardiovascular disease. *Eur Heart J* 2015; **36**: 83–93b.
- 9 Hamanaka RB, Mutlu GM. Particulate matter air pollution: effects on the cardiovascular system. *Front Endocrinol* 2018; **9**: 680.
- 10 Sun Q, Yue P, Deiluiis JA, et al. Ambient air pollution exaggerates adipose inflammation and insulin resistance in a mouse model of diet-induced obesity. *Circulation* 2009; **119**: 538–46.
- 11 Xu X, Liu C, Xu Z, et al. Long-term exposure to ambient fine particulate pollution induces insulin resistance and mitochondrial alteration in adipose tissue. *Toxicol Sci* 2011; **124**: 88–98.
- 12 Puett RC, Hart JE, Schwartz J, Hu FB, Liese AD, Laden F. Are particulate matter exposures associated with risk of type 2 diabetes? *Environ Health Perspect* 2011; **119**: 384–89.
- 13 Chen H, Burnett RT, Kwong JC, et al. Risk of incident diabetes in relation to long-term exposure to fine particulate matter in Ontario, Canada. *Environ Health Perspect* 2013; **121**: 804–10.
- 14 Weinmayr G, Hennig F, Fuks K, et al. Long-term exposure to fine particulate matter and incidence of type 2 diabetes mellitus in a cohort study: effects of total and traffic-specific air pollution. *Environ Health* 2015; **14**: 53.
- 15 Clark C, Sbihi H, Tamburic L, Brauer M, Frank LD, Davies HW. Association of long-term exposure to transportation noise and traffic-related air pollution with the incidence of diabetes: a prospective cohort study. *Environ Health Perspect* 2017; **125**: 087025.
- 16 Shaddick G, Thomas ML, Green A, et al. Data integration model for air quality: a hierarchical approach to the global estimation of exposures to ambient air pollution. *Appl Stat* 2018; **67**: 231–53.
- 17 GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; **396**: 1223–49.
- 18 Zheng P, Barber R, Sorensen RJD, Murray CJL, Aravkin AY. Trimmed constrained mixed effects models: formulations and algorithms. *J Comput Graph Stat* 2021; **30**: 544–56.
- 19 Honda T, Pun VC, Manjourides J, Suh H. Associations between long-term exposure to air pollution, glycosylated hemoglobin and diabetes. *Int J Hyg Environ Health* 2017; **220**: 1124–32.
- 20 Park SK, Adar SD, O'Neill MS, et al. Long-term exposure to air pollution and type 2 diabetes mellitus in a multiethnic cohort. *Am J Epidemiol* 2015; **181**: 327–36.
- 21 Krämer U, Herder C, Sugiri D, et al. Traffic-related air pollution and incident type 2 diabetes: results from the SALIA cohort study. *Environ Health Perspect* 2010; **118**: 1273–79.
- 22 Coogan PF, White LF, Jerrett M, et al. Air pollution and incidence of hypertension and diabetes mellitus in black women living in Los Angeles. *Circulation* 2012; **125**: 767–72.
- 23 Andersen ZJ, Raaschou-Nielsen O, Kettel M, et al. Diabetes incidence and long-term exposure to air pollution: a cohort study. *Diabetes Care* 2012; **35**: 92–98.

- 24 Yin P, Brauer M, Cohen A, et al. Long-term fine particulate matter exposure and nonaccidental and cause-specific mortality in a large national cohort of Chinese men. *Environ Health Perspect* 2017; **125**: 117002.
- 25 Yang B-Y, Fan S, Thiering E, et al. Ambient air pollution and diabetes: a systematic review and meta-analysis. *Environ Res* 2020; **180**: 108817.
- 26 Bowe B, Xie Y, Li T, Yan Y, Xian H, Al-Aly Z. The 2016 global and national burden of diabetes mellitus attributable to PM<sub>2.5</sub> air pollution. *Lancet Planet Health* 2018; **2**: e301–12.
- 27 Pope CA 3rd, Burnett RT, Krewski D, et al. Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: shape of the exposure–response relationship. *Circulation* 2009; **120**: 941–48.
- 28 Ambrose JA, Singh M. Pathophysiology of coronary artery disease leading to acute coronary syndromes. *F1000Prime Rep* 2015; **7**: 08.
- 29 Pinault LL, Weichenthal S, Crouse DL, et al. Associations between fine particulate matter and mortality in the 2001 Canadian Census Health and Environment Cohort. *Environ Res* 2017; **159**: 406–15.
- 30 Hoek G, Krishnan RM, Beelen R, et al. Long-term air pollution exposure and cardio-respiratory mortality: a review. *Environ Health* 2013; **12**: 43.
- 31 Forouzanfar MH, Afshin A, Alexander LT, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; **388**: 1659–724.
- 32 US Environmental Protection Agency. Integrated science assessment (ISA) for particulate matter (first external review draft, Oct 2018). 2018. <https://cfpub.epa.gov/ncea/isa/recordisplay.cfm?deid=341593> (accessed April 15, 2019).